Roles of CXCL5 on migration and invasion of liver cancer cells

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Xu, Xiaojing ^a   Huang, Peixin ^a   Yang, Biwei ^a   Wang, Xiangdong ^b   Xia, Jinglin ^a  

^a FUDAN UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

CXCL5; CXCR2; Invasion; Liver cancer; Migration

Indexed keywords

CHEMOKINE RECEPTOR CXCR2; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RECOMBINANT PROTEIN; SMALL INTERFERING RNA; CXCL5 PROTEIN, HUMAN;

ARTICLE; AUTOCRINE EFFECT; CELL MIGRATION; CHEMOTAXIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE EXPRESSION; GENE MAPPING; HUMAN; HUMAN CELL; INFLAMMATION; LIVER CANCER; LIVER CANCER CELL LINE; LIVER CARCINOGENESIS; METASTASIS; METASTASIS POTENTIAL; MICROARRAY ANALYSIS; PARACRINE SIGNALING; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR INVASION; LIVER TUMOR; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

BLOTTING, WESTERN; CHEMOKINE CXCL5; HUMANS; LIVER NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; POLYMERASE CHAIN REACTION;

EID: 84903870509     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-12-193     Document Type: Article

References (33)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. McGlynn KA, London WT. Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2005, 19:3-23.
3. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 2005, 25:143-154.
4. Berasain C, Castillo J, Perugorria MJ, Latasa MU, Prieto J, Avila MA. Inflammation and liver cancer: new molecular links. Ann N Y Acad Sci 2009, 1155:206-221.
5. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
6. Akiba J, Yano H, Ogasawara S, Higaki K, Kojiro M. Expression and function of interleukin-8 in human hepatocellular carcinoma. Int J Oncol 2001, 18:257-264.
7. Liu H, Pan Z, Li A, Fu S, Lei Y, Sun H, Wu M, Zhou W. Roles of chemokine receptor 4 (CXCR4) and chemokine ligand 12 (CXCL12) in metastasis of hepatocellular carcinoma cells. Cell Mol Immunol 2008, 5:373-378.
8. Walz A, Burgener R, Car B, Baggiolini M, Kunkel SL, Strieter RM. Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8. J Exp Med 1991, 174:1355-1362.
9. Zhou SL, Dai Z, Zhou ZJ, Wang XY, Yang GH, Wang Z, Huang XW, Fan J, Zhou J. Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma. Hepatology 2012, 56:2242-2254.
10. Park JY, Park KH, Bang S, Kim MH, Lee JE, Gang J, Koh SS, Song SY. CXCL5 overexpression is associated with late stage gastric cancer. J Cancer Res Clin Oncol 2007, 133:835-840.
11. Begley LA, Kasina S, Mehra R, Adsule S, Admon AJ, Lonigro RJ, Chinnaiyan AM, Macoska JA. CXCL5 promotes prostate cancer progression. Neoplasia 2008, 10:244-254.
12. Kawamura M, Toiyama Y, Tanaka K, Saigusa S, Okugawa Y, Hiro J, Uchida K, Mohri Y, Inoue Y, Kusunoki M. CXCL5, a promoter of cell proliferation, migration and invasion, is a novel serum prognostic marker in patients with colorectal cancer. Eur J Cancer 2012, 48:2244-2251.
13. Kuo PL, Chen YH, Chen TC, Shen KH, Hsu YL. CXCL5/ENA78 increased cell migration and epithelial-to-mesenchymal transition of hormone-independent prostate cancer by early growth response-1/snail signaling pathway. J Cell Physiol 2011, 226:1224-1231.
14. Xiong YQ, Sun HC, Zhang W, Zhu XD, Zhuang PY, Zhang JB, Wang L, Wu WZ, Qin LX, Tang ZY. Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells. Clin Cancer Res 2009, 15:4838-4846.
15. Tian J, Tang ZY, Ye SL, Liu YK, Lin ZY, Chen J, Xue Q. New human hepatocellular carcinoma (HCC) cell line with highly metastatic potential (MHCC97) and its expressions of the factors associated with metastasis. Br J Cancer 1999, 81:814-821.
16. Qin L. Osteopontin is a promoter for hepatocellular carcinoma metastasis: a summary of 10 years of studies. Front Med 2014, 8:24-32.
17. Snoussi K, Mahfoudh W, Bouaouina N, Fekih M, Khairi H, Helal AN, Chouchane L. Combined effects of IL-8 and CXCR2 gene polymorphisms on breast cancer susceptibility and aggressiveness. BMC Cancer 2010, 10:283.
18. O'Hayer KM, Brady DC, Counter CM. ELR + CXC chemokines and oncogenic Ras-mediated tumorigenesis. Carcinogenesis 2009, 30:1841-1847.
19. Frick VO, Rubie C, Wagner M, Graeber S, Grimm H, Kopp B, Rau BM, Schilling MK. Enhanced ENA-78 and IL-8 expression in patients with malignant pancreatic diseases. Pancreatology 2008, 8:488-497.
20. Liu Z, Yang L, Xu J, Zhang X, Wang B. Enhanced expression and clinical significance of chemokine receptor CXCR2 in hepatocellular carcinoma. J Surg Res 2011, 166:241-246.
21. Pappa CA, Tsirakis G, Kanellou P, Kaparou M, Stratinaki M, Xekalou A, Alegakis A, Boula A, Stathopoulos EN, Alexandrakis MG. Monitoring serum levels ELR + CXC chemokines and the relationship between microvessel density and angiogenic growth factors in multiple myeloma. Cytokine 2011, 56:616-620.
22. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008, 14:6735-6741.
23. Vinader V, Afarinkia K. The emerging role of CXC chemokines and their receptors in cancer. Future Med Chem 2012, 4:853-867.
24. Cheng WL, Wang CS, Huang YH, Tsai MM, Liang Y, Lin KH. Overexpression of CXCL1 and its receptor CXCR2 promote tumor invasion in gastric cancer. Ann Oncol 2011, 22:2267-2276.
25. Halpern JL, Kilbarger A, Lynch CC. Mesenchymal stem cells promote mammary cancer cell migration in vitro via the CXCR2 receptor. Cancer Lett 2011, 308:91-99.
26. Wente MN, Keane MP, Burdick MD, Friess H, Buchler MW, Ceyhan GO, Reber HA, Strieter RM, Hines OJ. Blockade of the chemokine receptor CXCR2 inhibits pancreatic cancer cell-induced angiogenesis. Cancer Lett 2006, 241:221-227.
27. Yang G, Rosen DG, Liu G, Yang F, Guo X, Xiao X, Xue F, Mercado-Uribe I, Huang J, Lin SH, Mills GB, Liu J. CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin Cancer Res 2010, 16:3875-3886.
28. Saintigny P, Massarelli E, Lin S, Ahn YH, Chen Y, Goswami S, Erez B, O'Reilly MS, Liu D, Lee JJ, Zhang L, Ping Y, Behrens C, Solis Soto LM, Heymach JV, Kim ES, Herbst RS, Lippman SM, Wistuba II, Hong WK, Kurie JM, Koo JS. CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. Cancer Res 2013, 73:571-582.
29. Maxwell PJ, Gallagher R, Seaton A, Wilson C, Scullin P, Pettigrew J, Stratford IJ, Williams KJ, Johnston PG, Waugh DJ. HIF-1 and NF-kappaB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells. Oncogene 2007, 26:7333-7345.
30. Acosta JC, O'Loghlen A, Banito A, Guijarro MV, Augert A, Raguz S, Fumagalli M, Da CM, Brown C, Popov N, Takatsu Y, Melamed J, d'Adda di Fagagna F, Bernard D, Hernando E, Gil J. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 2008, 133:1006-1018.
31. Mantovani A, Romero P, Palucka AK, Marincola FM. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 2008, 371:771-783.
32. McCarthy N. Tumour microenvironment: target practice. Nat Rev Cancer 2011, 11:315.
33. Roussos ET, Condeelis JS, Patsialou A. Chemotaxis in cancer. Nat Rev Cancer 2011, 11:573-587.